Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study

Size: px

Start display at page:

Download "Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study"

Buddy Newton
5 years ago
Views:

1 Published Ahead of Print on March 11, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation. Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study by Claire Oudin, Pascal Auquier, Yves Bertrand, Philippe Chastagner, Justyna Kanold, Marilyne Poirée, Sandrine Thouvenin, Stephane Ducassou, Dominique Plantaz, Marie-Dominique Tabone, Jean-Hugues Dalle, Virginie Gandemer, Patrick Lutz, Anne Sirvent, Virginie Villes, Vincent Barlogis, André Baruchel, Guy Leverger, Julie Berbis, and Gérard Michel Haematologica 2016 [Epub ahead of print] Citation: Oudin C, Auquier P, Bertrand Y, Chastagner P, Kanold J, Poirée M, Thouvenin S, Ducassou S, Plantaz D, Tabone MD, Dalle JH, Gandemer V, Lutz P, Sirvent A, Villes V, Barlogis V, Baruchel A, Leverger G, Berbis J, and Michel. Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study. Haematologica. 2016; 101:xxx doi: /haematol Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

2 ƒ Š Ž ƒ Š Ž Š ƒ Ž ƒ K d d W d z d W d : < d D W e ^ d e ^ e W e D d dd :, dd s ' dd W > dd ^ dd s s d s d d dd ' > dd : d ' D d d d W, K d, D h D & d Z h ddee W, D h d, D & d W, K h, > & d W K, s > E & d W, K // dh, & & ew, h, > E & e W, h, ^ & e W, K h, & e W, K h, ' & dd W, d, W & dd W, Z, W & dd W, K h, Z & dd W, h, ^ & dd W, h, D & Z Kh/E D W, K d, dedz ^ W dddedd & d

3 D W ldddeddeeeee & ldddeddedeee t dede t ddd d & e ^ d d d > ^ d d & E Z W & E / / & E Z EZ W Z W, > & / W, Z /Z^W d

4 d, t dee d e d, de dl edl / d d el edl / d de e dd dd W,Z d ee ld dd d ee ld W,Z d de ld W dd,z d ed ld d de d dl d e el edl/ e d d t,z d ed ld d d Edddededee d

5 d d e dd d dd, de /, D de de > t d e de de d & > > d

6 Š t > d > dd & deed dd & dd d d > dd ddd d & E W Z E / d d d & dd dd > W d d^, dd h d^, m d /h dd m dd d^, mdd d^, d / D ^ ^W^^d ^W^^/ /> h^ / ^ e d t χ d & d

7 Y D t h W edl / < D edl/ d d,,z edl/ md Ž d W eed dd& dee ee dl dddd dddd ddd ed dl W d d ed el de dl ee dl de el d / e e d de e d e d de d W ' d d W d ddee de el W ee ed dl e

8 e d el, ed ee ddd >, de dl edl/ d d el edl/ d de e d e e e d d d d d d e d K ', t & d dd de el edl/ d d de dl edl/ e d d dl edl/ d e d mdd d dl edl/ e ed d dl edl/ d e de d ld d & d / & d / d d K dd de ld de W d d lddd dl d lddd dl d ldd d el d ldee de dl d ld el d d d ee edl/ d e ee e

9 ld d ee edl/ d de e d ld d de edl/ d e ld / d de ld W W d ed ld d d d W t d / mdd d d d d d d W ded dl d e de e K ded de el de de dl de d d d el dd d e d e e el e d d dd & d d d de d d W E Z / dd d dl edl/ d e e d de dl edl/ e de e

10 md d d > de d d, e dl d dl d el d dl,z d ed ld d d d d d dee t dee ld ed ld ee e

11 t & d, de el K & d el d dl dd K ^ ^ ddee e dl e el de el dd, el edl/ d de e d d dd d el W dd, de dd d d d de d d e de, /,Zld de ld d dd

12 de d de dd d, ^ de de dd &, Z de eed ddl Š ddl d ^ d / el ddl de de dd d d d d de D ld /,Zld de ld d d dd

13 / d / >, d de de dd t,zld ed ld de de dd E d & d^, dd E dd t e d d de dd, ^ de ed eed / de t / d d dddd d e dddd de D de de, / / de d dl ddd / de d de de dd ^ dd

14 de /,Zld ed ld d dd de E d de d d de d d d dd d e d de d d Z dd E de d dd e dd d de de t t ^ & de / de dd > d d, t ^ d^, dd d^, d^, dd

15 E d^, / W dd

16 dd d W, W ^ :d Z : K dd eede ee d & > ^ t :& ' d, > ^ > ^ > ddded ee deed deee d W > :D, d deee ed d e d : & > ^ D Z ^ ^ W ddde d ddde d >, < E < d K ddd e & > < t d D : D W K ddee d ed ee e s D> D> ' ^, deee de e ddee dded e D & D / W D ^ & d : / deee d ddde e W d D :W deed dde e eed eee ^ D & Z h Z < W,^ D : : D ddee d dde d ^ : Z D D W ^ ^ > ddded edee dddd ^ ' Z,: E : K ddde d dde dde Z D & Z Dd> t W ^ : K ddde de ddde dd D >D > WD : ^ d : ddde e dded dded

17 de, ^> Z^ D /Z d, E :D deed de dee e de ^ t : D, ^ ^ : D dded e ddde dd de ^ :, W t d ddde dd dde dde de ^ D ' Z d d D d dde ede e de E Z <^ < ^ D W: t & d W, K deee d d de : D ' W & > / : ddd de de D ' W ^ D, D d ddde e eee e ^ Z ^ :> d W dded d dd s W ^ < ^, ^ d & ^h s/ Dy W dded e dee dee : > t ^ < W dded d dd t ^ Z ddde d Zddde de Z > E D: ^,E D d K :, ' d >> W deed de ddee de, D K / E W / : ddee^ dde d de <^ E << t > D d ^ ^ > dd ddde ddde de > ' : > d D d dd eed eed

18 de /, z z d z > : D ddee deed deee s D :, D : dddee d dd ^,D s d D' E : D ddee e dede deed D > ^ t <& > Wt ^ > d : D ddee e deed deed ^ D/ K ', ^ :D ddded d dde dde E ' ^d D d ddde dd^ d ^de de ^ ^: > ' D K Z Z ddd dd de / ' h : D ddde ed dede de d : W W D Z ^ ^ / : ddde d dddd de s >, W Z D W ddd ed d ^ ^ < > Y D d ddee ddee dd ' <t > ^, d : W ^ ddde dded dded ^ D: W E :D deee dde d dee dde Z > :, ^ Z d Z Z deed dd dde dee ^ > : d : D deee ed ddddde

19 , DZ Z : > ', : D ddde ed d ede e de

20 , h ldee E l l edl/ l ' edl/ D d e e e de e d e & d d de de d d e d d de d > de d d e e d d e d e ee d d de de e e d de d d e m ed d de d d d de d d e m e d de d e e e de d d de e,,^d de de e d e e de d e e ed e d ed d de d de e e de d d d,^d d/ E^ e e d e d d d d d d e de d E^,^d e d d dd d d e e d d d e d,^d d/ E^ e e mdd d d e de d e e ee d,^d d/ E^ ed e de d d e d de e e,^d d/ E^ e de e d e d d d e ed d E^ e d e d d e d e e e e d d de e e d d de d de d e d de d E^ de e d d d d e d d e d e e d e e d e d e d de d K d de d d de d e e ee d d e e ee d d d h ldee E^,^d de

21 s E l,z edl/ m ded ed d d m dde de e d ed d d ed d dd ' D ddd de e d & dde d d dd d ee d dd d de > ddd ed d d dde e d ed d d dd d dd d,^d d/ E^ ddd d d E^,^d ddd d d de d de d ed d dd,^d d/ E^ dd d e d ee d e ee d dd,^d d/ E^ dee de d d ee d de e dd d dd,^d d/ E^ dd d e d de d e dd d dd d d Z ldee E^,^d d/ / dd

22 d h ld E l l edl/ l ' edl/ D d d e mdd d d d d d d e d d d e e d & e e e d d e d de d e de d > e d d d dd d e d d e d d e e d d d e d d e e e e d d e m de d e d ed d d d d e e d e d de d m e d d d e d d e e e d d d d,,^d e d d de e d d e de d e d d d d d d d e d d e d d e e d d,^d d/ E^ d d d d de d e d e d e d d d de d E^,^d d d d d d d d e d e d d d de d,^d d/ E^ d d e d d d de d e d d d de d,^d d/ E^ de e d d d d e d d e e d,^d d/ E^ d d d d d d E^ e d e d ed d e d e d e d d e de d d d d d e d d de e d e d d de e E^ de e e d d dd d e d d d e d d d de d d d d d d d d K d d d d d d d d h ld E^,^d d/ dd

23 s E l,z edl/ W m dde ed d d m dee de d d ee d de d dd d ee ' D ded de e d & dde d d ed d ee ed d ddd > ded ee d d dde d d de d d de d de d,^d d/ E^ ee de e d E^,^d dde e d ed d d ee d ed,^d d/ E^ de d e d de d de ee d de,^d d/ E^ ddd e d dd d ed ed d de,^d d/ E^ dd d d ee d de dd d d d D / md E^,^d d/ dd

24 > & d E^,^d mdd d d/ & d ld ld d E^l & d l E^l & d md ddd dd

27 Supplemental data Supplemental methods Data regarding disease type, treatment modalities, irradiation modalities, and transplantation procedure were collected from the medical records. The chemotherapy protocol and the conditioning regimen depended on the protocols used at the time of transplantation, the underlying disease, disease status, and history of central nervous system irradiation involvement. The central nervous system irradiation dose (18 or 24 grays), field (cranial or cranio-spinal) and indication depended on the protocol used at the time of treatment.

28 Gender Hypothyroidism evaluation Thyroid cancer evaluation Participants group (n=588) Non participants group (n=77) p- value Participants group (n=502) Non participants group (n=163) Male n (%) 340 (57.8) 38 (49.3) (56.6) 94 (57.7) 0.81 Female n (%) 248 (42.2) 39 (50.7) 218 (43.4) 69 (42.3) Leukemia type Acute myeloid leukemia n (%) 146 (24.8) 15 (19.5) (23.5) 43 (26.4) 0.46 Acute lymphoid leukemia n (%) 442 (75.2) 62 (80.5) 384 (76.5) 120 (73.6) Relapse p- value Yes 237 (40.3) 13 (16.9) < (41.2) 43 (26.4) No 351 (59.7) 64 (83.1) 295 (58.5) 120 (73.6) Age at leukemia diagnosis (years) 6.5 ( ( ± ± Median (min-max) 11.2) 11.7) Treatment modality CNS irradiation, no HSCT n (%) 143 (24.3) 51 (66.2) < (23.7) 75 (46) <10-3 HSCT with TBI, with previous CNS irradiation n (%) 21 (3.6) 2 (2.6) 19 (3.8) 4 (2.5) HSCT with TBI, without previous CNS irradiation n (%) 289 (49.1) 8 (10.4) 255 (30.9) 42 (25.8) HSCT without TBI, with previous CNS irradiation n (%) 15 (2.6) 1 (1.3) 10 (2) 6 (3.7) HSCT without TBI, without previous CNS irradiation n (%) 120 (20.4) 15 (19.5) 99 (19.7) 36 (22.1) Age at transplantation/irradiation < 10 years n (%) 361 (61.4) 50 (64.9) (61) 105 (64.4) years n (%) 227 (38.6) 27 (35.1) 196 (39) 58 (35.6) Hematopoietic stem cell transplantation (HSCT) type Autologous n(% of transplanted patients) 91 (20.4) 1 (3.8) (18.3) 22 (25) 0.15 Allogeneic n(% of transplanted patients) 354 (79.6) 25 (96.2) 313 (81.7) 66 (75) Age at transplantation (years) 8.8 ± ± ± ± Conditioning regimen before HSCT TBI-based n(% of transplanted patients) 310 (69.7) 10 (38.5) (71.5) 46 (52.3) <10-3 Non-TBI based n(% of transplanted patients) 135 (30.3) 16 (61.5) 109 (28.5) 42 (47.7) Central nervous system (CNS) irradiation Yes n (%) 179 (30.4) 54 (70.1) < (29.5) 85 (52.1) <10-3 No n (%) 409 (69.6) 23 (29.9) 354 (70.5) 78 (47.9) Age at CNS irradiation (years) 8.5 ± ± ± ± CNS irradiation type Cranial irradiation n(% of CNS irradiation recipients) Cerebro spinal irradiation n(% of CNS irradiation recipients) Unknown n(% of CNS irradiation recipients) CNS irradiation dose 18 grays n(% of CNS irradiation recipients) 24 grays n(% of CNS irradiation recipients) 122 (68.2) 41 (75.9) (71.6) 57 (67) (29.6) 12 (22.2) 39 (26.4) 26 (30.6) 4 (2.2) 1 (1.9) 3 (2) 2 (2.4) 134 (74.9) 39 (72.2) (77) 59 (69.4) (20.1) 7 (13) 23 (15.5) 20 (23.5)

29 Other n(% of CNS irradiation recipients) 8 (4.5) 6 (11.1) 9 (6.1) 5 (5.9) Time from diagnosis to last visit (years) 12.6 [ [ [ [ Median (min-max) 18.8] 21.3] 19.1] 19.1] 0.45 Supplemental Table 1. Patients characteristics. Comparison between participant and non participant patients. CNS: central nervous system; HSCT: hematopoietic stem cell transplantation; TBI: total body irradiation

30 2162 patients with a new LEA evaluation during years patients treated with chemotherapy only (not eligible) 665 eligible patients treated with CNS irradiation and/or HSCT Thyroid function analysis Thyroid tumor analysis 77 patients who had no complete thyroid function evaluation (eligible not included in function analysis) 163 patients who had no thyroid tumor evaluation (eligible not included in tumor analysis) 588 patients with at least one thyroid function evaluation (included in thyroid function analysis) 502 patients with at least one thyroid tumor evaluation by ultrasound scan (included in thyroid tumor analysis) Supplemental figure: flow chart. CNS: central nervous system, HSCT: hematopoietic stem cell transplantation

31 Number (%) p-value 10 years Cumulative incidence (%) [95%CI] 20 years Cumulative incidence (%) [95%CI] Gender Male 49 (14.5) 15.0 [ ] 18.4 [ ] Female 50 (20.4) [ ] 28.8 [ ] Leukemia type Acute myeloid leukemia 15 (10.3) 11.4 [ ] 14.5 [ ] Acute lymphoid leukemia 84 (19.2) [ ] 25.3 [ ] Age at transplantation/irradiation < 10 years 71 (19.8) 18.6 [ ] 26.2 [ ] 10 years 28 (12.5) [ ] 16.9 [ ] Hematopoietic stem cell transplantation type Autologous 22 (25.3) 20.6 [ ] 25.3 [ ] Allogeneic 71 (20.2) [ ] 32.5 [ ] Treatment modality HSCT without TBI. without previous CNS irradiation 9 (7.5) 7.0 [ ] 12.1 [ ] CNS irradiation. no HSCT 6 (4.2) 1.0 [ ] 5.0 [ ] HSCT with TBI. with previous CNS irradiation 6 (33.3) < [ ] 30.0 [ ] HSCT with TBI. without previous CNS irradiation 72 (25.1) 28.4 [ ] 34.7 [ ] HSCT without TBI. with previous CNS irradiation 6 (42.9) 14.9 [ ] 39.8 [ ] CNS irradiation type Cranial irradiation 10 (8.4) 3.7 [ ] 8.1 [ ] Cerebro spinal irradiation 7 (13.5) [ ] 17.6 [ ] CNS irradiation dose 18 grays 7 (5.4) 2.8 [ ] 7.0 [ ] 24 grays 8 (22.2) 6.8 [ ] 23.9 [ ] Other 3 (37.5) [ ] 25.0 [ ]

32 Supplemental Table 2. Univariate analysis: risk factors for primary hypothyroidism (n=582). CNS: central nervous system; HSCT: hematopoietic stem cell transplantation; TBI: total body irradiation

33 Variables N % ahr 95%CI p-value Age at transplantation/irradiation < 10 years years Gender Male Female Leukemia type Acute lymphoid leukemia Acute myeloid leukemia Treatment modality HSCT without TBI, without previous CNS irradiation CNS irradiation, no HSCT HSCT with TBI, with previous CNS irradiation HSCT with TBI, without previous CNS irradiation HSCT without TBI, with previous CNS irradiation Supplemental Table 3. Risk factors for primary hypothyroidism: multivariate analysis (n=582). CNS: central nervous system; HSCT: hematopoietic stem cell transplantation; TBI: total body irradiation. In bold: significant values

34 The L.E.A study group Marseille: ALLOIN Anne-Lise, AUQUIER Pascal, BARLOGIS Vincent, BERBIS Julie, CHAMBOST Hervé, CURTILLET Catherine, ESMIOL Sophie, GALAMBRUN Claire, GARNIER Floriane, MICHEL Gérard, ORBICINI Delphine, OUDIN Claire, THURET Isabelle, VERCASSON Camille, VILLES Virginie, Nancy: CHASTAGNER Pascal, CLEMENT Laurence, CONTET Audrey, FOUYSSAC Fanny, LEMELLE Irène, MANSUY Ludovic, PERNET Marjolaine, PERROT Aurore, PHULPIN Aurélie, POCHON Cécile, SCHMITT Claudine, SERRIER Caroline, Nice: BELLMANN-ROQUEPLAN Françoise, DEVILLE Anne, HATHROUBI Chokri, LE MEIGNEN-DIOP Marion, MONPOUX Fabrice, POIREE Maryline, ROHRLICH Pierre-Simon, SOLER Christine, Clermont-Ferrand: CHAMBON Fanny, DORE Eric, ISFAN Florentina, KANOLD Justyna, ROUEL Nadège, Grenoble: ADJAOUD Dalila, ARMARI-ALLA Corinne, CACACE Sophie, PAGNIER Anne, PLANTAZ Dominique, SCHIFF Isabelle, Lyon: BERTRAND Yves, GARNIER Nathalie, HALFON-DOMENECH Carine, HU Julie-Yi, KEBAÏLI Kamila, RENARD Cécile, Paris Trousseau: AUVRIGNON Anne, BOUAYAD AGHA Latéfa, DOLLFUS Catherine, DONADIEU Jean, FASOLA Sylvie, LANDMAN-PARKER Judith, LEVERGER Guy, PELLEGRINO Béatrice, PETIT Arnaud, TABONE Marie Dominique, St Etienne: BERGER Claire, DAVID Audrey, ODIER Françoise, STEPHAN Jean Louis, THOUVENIN-DOULET Sandrine, Rennes: BAYART Sophie, BONNEAU Jacinthe, CHAPPE Céline, GANDEMER Virginie, LAMOUR Anne- Marie, SOK-FEDELE Phaktra, TAQUE Sophie, TOUTAIN Fabienne, Montpellier: HAOUY Stéphanie, MOPHAWE Ornellia, SAUMET Laure, SIRVENT Nicolas, SIRVENT Anne, Paris St Louis Robert Debré: BARUCHEL André, BRETHON Benoît, LEBLANC Thierry, MOUKOKO Marie- Noelle, RAY-LUNVEN Anne-France, AVRAN David, AZARNOUSH Saba, CUINET Aurélie, DALLE Jean- Hugues, DUQUESNE Frédérique, FAHD Raymonda, LESCOEUR Brigitte, OUACHEE-CHARDIN Marie, YAKOUBEN Karima, Bordeaux: ALADJIDI Nathalie, ANSOBORLO Sophie, DE BOUYN-ICHER Céline, DUCASSOU Stéphane, JUBERT Charlotte, MERCHED Maria, NOTZ-CARRERE Anne, PEREL Yves, VERITE-GOULARD Cécile, Strasbourg: CERON-DURAN Sofia, LUTZ Patrick, PAILLARD Catherine, SPIEGEL Alexandra, Angers: BERARDI Elsa, BRASME Jean-François, COLIN Laure, DE CARLI Emilie, DUPLAN Mylène, PELLIER Isabelle, PROUST-HOUDEMONT Stéphanie.

Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA

Published Ahead of Print on October 6, 2016, as doi:10.3324/haematol.2016.152256. Copyright 2016 Ferrata Storti Foundation. Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes